key: cord-0942624-tg5z3obt
authors: Kumar, Sumit; Sharma, Prem Prakash; Shankar, Uma; Kumar, Dhruv; Joshi, Sanjeev K.; Pena, Lindomar; Durvasula, Ravi; Kumar, Amit; Kempaiah, Prakasha; Poonam,; Rathi, Brijesh
title: Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure–Activity Relationship Studies
date: 2020-06-02
journal: J Chem Inf Model
DOI: 10.1021/acs.jcim.0c00326
sha: 704e01b0be00d91ceed52c72e96c6d3cebee2a77
doc_id: 942624
cord_uid: tg5z3obt

[Image: see text] The novel coronavirus, SARS-CoV-2, has caused a recent pandemic called COVID-19 and a severe health threat around the world. In the current situation, the virus is rapidly spreading worldwide, and the discovery of a vaccine and potential therapeutics are critically essential. The crystal structure for the main protease (M(pro)) of SARS-CoV-2, 3-chymotrypsin-like cysteine protease (3CL(pro)), was recently made available and is considerably similar to the previously reported SARS-CoV. Due to its essentiality in viral replication, it represents a potential drug target. Herein, a computer-aided drug design (CADD) approach was implemented for the initial screening of 13 approved antiviral drugs. Molecular docking of 13 antivirals against the 3-chymotrypsin-like cysteine protease (3CL(pro)) enzyme was accomplished, and indinavir was described as a lead drug with a docking score of −8.824 and a XP Gscore of −9.466 kcal/mol. Indinavir possesses an important pharmacophore, hydroxyethylamine (HEA), and thus, a new library of HEA compounds (>2500) was subjected to virtual screening that led to 25 hits with a docking score more than indinavir. Exclusively, compound 16 with a docking score of −8.955 adhered to drug-like parameters, and the structure–activity relationship (SAR) analysis was demonstrated to highlight the importance of chemical scaffolds therein. Molecular dynamics (MD) simulation analysis performed at 100 ns supported the stability of 16 within the binding pocket. Largely, our results supported that this novel compound 16 binds with domains I and II, and the domain II–III linker of the 3CL(pro) protein, suggesting its suitability as a strong candidate for therapeutic discovery against COVID-19.

Coronaviruses (CoV) belong to a group of viruses consisting of a core of genetic material enveloped with a protein spike appearing like a crown, which means "corona" in Latin. 1 A diverse variety of coronaviruses is known, which causes mild respiratory diseases and sometimes gastrointestinal symptoms in different animal species. In humans, four CoV (229E, NL63, OC43, and HC HKU1) are endemic and cause respiratory diseases that can range from a common cold to lung failure, but the disease remains mild in most of the cases. 2, 3 However, other types of CoV, i.e., SARS-CoV (Severe Acute Respiratory Syndrome) and MERS-CoV (Middle East Respiratory Syndrome), can cause severe respiratory diseases as identified in China (2002) and Saudi Arabia (2012), respectively. 4 These viruses are bat-borne in nature and circulate in a range of animals and are sometimes transmitted from animals to humans (i.e., SARS-CoV transmitted to humans from civet cats 5 and MERS-CoV from dromedary camels). 6 In December 2019, a cluster of pneumonia cases were observed in a group of people associated with seafood and an animal market in China. 7 Subsequently, the outbreak was attributed to a novel Special Issue: COVID19 -Computational Chemists Meet the Moment CoV and related to the SARS virus based on its genetic similarities with a previous known coronavirus (SARS-CoV). 8 Later, the disease was named as COVID-19 by the World Health Organization (WHO) caused by a novel coronavirus, SARS-CoV-2. 9 The outbreak started in Wuhan, China, and rapidly escalated to other countries. The USA, Spain, Russia, UK, Italy, France, and Brazil lead with the highest number of COVID-19 cases officially reported. COVID-19 caused approximately 2924 deaths, and 85,403 confirmed cases were identified with a mortality ratio of 3.42% until the end of February 2020 across the countries. 10 The number of cases increased suddenly, and the disease was declared a pandemic by WHO on 11 March 2020. 11 As of 10 May 2020, a total of 38,55,788 confirmed cases have been noted all around the world, resulting in 2,65,862 deaths. 12 The number of confirmed cases has increased sharply, and also, the number of deaths due to COVID-19 can be clearly observed across the world during the month of April 2020 as shown in Figure 1 . 13 Major symptoms of this disease include high fever, cough, and shortness of breath, whereas in severe cases pneumonia and kidney failure are the major cause for death. 14 However, in many cases, the basic symptoms of this deadly disease were not observed, and asymptomatic transmission of the virus from the infected person could be more dangerous. Although, a series of rapid and specific diagnostic tools are available for the COVID-19 disease, 15 vaccines and SARS-CoV-2 specific therapeutic treatments are not available. Recently, the crystal structure of the SARS-CoV-2 main protease, M pro , also called 3CL pro , complexed with an inhibitor N3 was released. 16 The 3CL pro enzyme of SARS-CoV-2 processes polyproteins by proteolytic action of replicase enzyme (pp1a and pp1ab) to release a functional polypeptide (Figure 2A) . 16 It is a dimeric protein, which contains two symmetric units designated as protomers. Each protomer has three domains, namely, domain I (residues 8−101), domain II (residues 102−184), and domain III (residues 201−303). Domain III comprises five α-helices and is linked with domain II through an extended loop region (residues 185−200). 3CL pro has Cys_145 and His_41 catalytic dyads, and a substrate-binding site is positioned in the cleft between domains I and II ( Figure 2B ). These descriptions match with the previously reported protease enzyme of SARS-CoV. 17−23 3CL pro of SARS-CoV-2 is an important drug target, and computer-aided drug design (CADD) is considered as an undisputable and significant approach to discover antiviral drug candidates. Identically, studies have been adopting various approaches for therapeutic discovery against SARS-CoV-2 through virtual screening. 33 ,34 Antiviral drugs such as HIV protease inhibitors 24 and approved drugs such as ribavirin, oseltamivir, and a few more have been studied against earlier reports for SARS-CoV. 25 In this article, we aim to perform a fast discovery of the potential candidates against 3CL pro of SARS-CoV-2 through virtual screening of approved antiviral therapeutics and build a focused library of novel potential compounds.

The protease structure, the 3-chymotrypsin-like cysteine protease (3CL pro ) enzyme of SARS-CoV-2 (PDB ID: 6LU7) with 2.1 Å, was obtained from the the Protein Data Bank at the RCSB site (http://www.rcsb.org). The computational work was performed using Schrodinger software.

2.1. Preparation of Protease Structure. The SARS-CoV-2 virus protein structure was prepared in the Protein Preparation Wizard and Prime module of the Schrodinger suite to remove defects such as missing hydrogen atoms, inappropriate bond order assignments, charge states, alignments of several groups, and missing side chains. 26, 27 Steric hindrance and strained bonds/angles were removed through restrained energy minimization, permitting movement in heavy atoms up to 0.3 Å.

2.2. Preparation of Antiviral Drugs and HEA Analogs for Virtual Screening. Approved antiviral drugs such as indinavir, saquinavir, nelfinavir, ritonavir, lopinavir, atazanavir, amprenavir, darunavir, nelfinavir, oseltamivir, tipranavir, fosamprenavir, and galidesivir were screened to select the hits as reference molecule or positive control for the design of novel compounds. The coordinate files of approved drugs were obtained from the Protein Data Bank at the RCSB site (http:// www.rcsb.org) and PubChem. 28, 29 Over 1000 analogs were prepared by the Maestro tool. The structures of both approved antiviral drugs and HEA analogs were prepared prior to docking by Ligprep. Ligprep assisted the production of 2D or 3D structures and their corresponding low-energy 3D structures, which were immediately available for Glide program applications. All the parameters were kept as the default except chirality parameters for the antiviral drugs and new HEA analogs. The chirality was kept as the default for the 3D structures, and all the combinations of chirality were developed for the approved antiviral drugs and new HEA analogs. Next, desalting, tautomer generation, and probable ionization states at pH 7 ± 2 were adjusted. 30 Ionization states of all the molecules were predicted by the Schrodinger suite inbuilt Epik module. 31 2.3. Molecular Docking of Compound Libraries against Target Protease Active Site. Site-specific molecular docking of approved antiviral drugs (Table 1 ) and novel HEA-based analogs ( Table 2 ) against protease was accomplished using the Glide module of the Schrodinger suite. The Glide tool was used for receptor grid preparation at default parameters, which include a van der Waals radius scaling factor (1.0) and partial charge cutoff (0.25). 32 The screening of both libraries was performed by Glide at extra precision (XP), which indicates an appropriate connection between excellent poses and good scores.

2.4. ADMET Calculations. Swiss ADME 33 and PKCSM 34 were employed to predict the ADMET (i.e., absorption, distribution, metabolism, excretion, and toxicity) profile of identified hit compounds (1−25) and two antiviral drugs (indinavir and atazanavir). The predicted ADMET properties includes molecular weight, H-bond acceptor, H-bond donors, predicted octanol/water partition coefficient (MLogP), TPSA (total polar surface area), Lipinski (drug-likeness), Rat LD 50 , and hepatotoxicity. The results are shown in Table 3 .

Simulation. An extensive 100 ns MD simulation was performed for the complex structure of the 6LU7 receptor with the selected approved drug (indinavir) and designed novel HEA compound (compound 16) using Desmond software (D. E. Shaw

Research, New York) to access the stability of binding for the ligand-6LU7 complex. 35 The system was solvated in a TIP3P water model and 0.15 M NaCl to mimic a physiological ionic concentration. The full system energy minimization step was done for 100 ps. The MD simulation was run for 100 ns at a 300 K temperature and standard pressure (1.01325 bar), within an orthorhombic box with buffer dimensions of 10 Å × 10 Å × 10 Å and NPT ensemble. The energy (kcal/mol) was recorded at an interval of 1.2 ps. Neutralization of the proteinligand complex system was achieved by adding Na + or Cl − counterions that balanced the net charge of the systems. The Nose−Hoover chain and Martyna−Tobias−Klein dynamic algorithm were used to sustain the temperature of all the systems at 300 K and pressure of 1.01325 bar, respectively.

The current COVID-19 pandemic urges the immediate therapeutic treatments to protect the health of people who are at high risk of infection, particularly when vaccines are still under development. To date, no specific therapeutic treatment is available, and current treatment includes supportive care, i.e., oxygen therapy, fluid management, use of approved antiviral drugs developed for Ebola (remdesivir), 36 anti-HIV (lopinavirritonavir), 37 and recently approved antimalaria drugs (hydroxychloroquine) 38 as a combination therapy. The combination of azithromycin and hydroxychloroquine was also shown as a partial treatment against COVID-19. 39 In order to develop targeted therapeutics, initially, design of compound libraries based on the available target protein structures and active binding moiety of the protein residues is an important step. Although it is hard to predict the potency and binding specificity from the structure of a chemical compound, structure-based design of novel bioactive scaffolds is considered as an important approach to accomplish adequate chemical diversity of compound libraries that facilitate SAR analysis. Of particular note, finding a potent molecule with drug-like properties remains challenging, and therefore, advanced drug discovery involves CADD approaches that accelerates the early discovery phases. The main protease, 3CL pro , of SARS-CoV-2 was presented as an attractive drug target, and a rapid identification of drug candidates was achieved through virtual screening. 33, 34 Encouraged with this, and exploiting a recently published crystal structure of 3CL pro from SARS-CoV-2 (PDB code 6LU7), 16 we executed virtual screening for the 13 antiviral drugs. The list of the compounds is presented in Table 1 .

3.1. Virtual Screening of Antiviral Drugs and New HEA Analogs against SARS-CoV-2 Protein 3CL pro . In the beginning, molecular docking of the approved antiviral drugs was carried out with protein 3CL pro using the Glide module of the Schrodinger suite. 32, 40 Docking score and Glide XP Gscore (kcal/mol) were considered as the measures for binding affinity to rank the poses of the ligands. Among the listed antiviral drugs, indinavir, which is an approved HIV-1 protease inhibitor, was realized as the best inhibitor based on a docking score and XP Gscore of −8.824 and −9.466 kcal/mol, respectively ( Table 1 , entry 1). The second rank was secured by another HIV-1 protease inhibitor, atazanavir, with a docking score of −7.912 and XP Gscore of −7.92 (Table 1 , entry 2). Our results were in agreement with the docking score of indinavir (−10.424) reported by Chang 41 and colleagues on AutoDock Vina. Interactions of indinavir with the 3CL pro protein are presented in Figure 3 . Indinavir showed H-bond 45, 46 With the presence of HEA in indinavir 47, 48 and our ongoing research toward the discovery of HEA analogs, a library of new HEA compounds (>2500) was designed and subjected to virtual screening against the 3CL pro protein. Of the screened >2500 new HEA analogs, 25 analogs exhibited a notable docking score over the indinavir score as shown in Table 2 and Table S1 .

Among the top-ranked analogs, compound 1 ( Table 2 , entry 1) was shown to possess the highest docking score (−9.864) and XP Gscore (−10.227 kcal/mol).

Next, to get an insight about the drug-likeness properties, all the 25 top-ranked analogs along with two antivirals (indinavir and atazanavir) were screened for their ADMET profiles, and the results are depicted in Table 3 . Notably, only compound 16 (Table 3 , entry 16) strictly abides to the Lipinski's "rule of five" and theoretically met the drug-likeness properties. Compound 4 ( Table 3 , entry 4) also followed the criteria with a slight deviation in number of rotatable bonds (i.e., 11). 49 However, compound 4 exhibited hepatoxicity. On the basis of the favorable physicochemical properties displayed, compound 16 was selected for further studies.

Compound 16 also offered an extra H-bond interaction and also enhanced hydrophobically packed H-bond 32 (Phob EnHB) interaction by −1.5. The phenyl group of a HEA moiety of compound 16 interacted with Leu_141 and Phe_140 residues by hydrophobic interactions (Table 4 , entry 2). The 4-fluoro-aniline scaffold was found to be packed deeply inside the pocket by hydrophobic interactions with Cys_44 and Cys_145 and pi-pi interaction with His-41 in domain I. Residues Cys_145, Ser_144, and Gly_143 interacted with carboxamide oxygen by H-bonds and His_164 in domain I with nitrogen of an aniline moiety as shown in Figure 4 .

Structure activity relationship (SAR) analysis was performed to designate the role of scaffolds present in HEA compounds. The lead compound 16 contains three main functionalities, i.e., HEA, anilines derivatives on pocket 1, and aromatic/aliphatic groups on pocket 2, as shown in Table 5 . First, the role of the HEA backbone was studied; one compound 33 ( Table 5, (Table 5, (Table 5 , enties 1−3 and 6). However, 26 was shown to possess an inferior docking score in comparison to compound 16 that contains a tert-butylacetate group at pocket 2, indicating more pronounced effects without fluorinated aromatic components. Therefore, on the basis of molecular docking, ADMET properties, and SAR analysis, compound 16 was identified as the most suitable analog and was considered for MD simulation study.

Studies. MD simulation at 100 ns was performed for indinavir-3CL pro and compound 16-3CL pro . The unligated-3CL pro complex was also considered for MD studies to identify the effect on simulations in the absence of ligands. There are several factors such as the conformation of ligands, water molecules, ions, cofactors, ligand protonation state, and conformational and solvation entropies that can affect in silico predictions in an unexpected pattern. Several reports are available to support the role of MD simulations for the refinement of docking results. 50, 51 MD simulations were carried out to determine the stability of the interactions of ligand-protein docked complexes. The final structures of simulated complexes exhibited strong stereochemical geometries of the residues as analyzed by the Ramachandran map ( Figure 5) .

The number and percentage of residues in favored, allowed, and outlier regions for these three systems are presented in Table 6 . The complexes of indinavir and unligated 3CL pro possess two (Gly_251, Thr_224) and three (Gly_11, Asn_84, Asp_187) outlier residues, respectively. Interestingly, there was no outlier residues for the 16-3CL pro complex ( Table 6 , entry 1). Further, the stability of the compound 16-3CL pro complex was monitored during the entire simulation process where total energy (E), potential energy (E_p), temperature (T), pressure (P), and volume (V) values were computed as shown in Figure  6 . The plots for the indinavir-3CL pro complex is displayed in the Supporting Information ( Figure S1 ). Notably, no significant change was observed in potential energy and total energy and other parameters for compound 16 and indinavir complexes, as the average values with a standard deviation of these parameters were found in same range (Supporting Information, Tables S2 and S3). While for entire simulations root mean square deviation (RMSD) change for Cα was also monitored. This parameter measures the global deviation of atoms from a reference status, i.e., frame 0. The RMSD plot indicated the fluctuations in the initial conformation of the receptor for all three systems until 30 ns (Figure 7) , which later stabilized in the production phase with average values of RMSD backbone (2.015 Å), RMSD Cα (1.993 Å), and RMSD side-chain (2.876 Å) for the 16-3CL pro complex. The average RMSD values for backbone, Cα, and side chain for indinavir-3CL pro and unligated-3CL pro complexes are depicted in the Supporting Information (Table S4 ). The RMSD of both Figure 8A . Protein-RMSF was monitored to assess the local residue flexibility, and ligand-RMSF was examined to study the atom-wise fluctuations in the ligand. With fluctuation of a dynamical system over the well-defined average position, the RMSD from the average over time may be referred as RMSF. 35 The RMSF values, "Fit on Protein" trend (brown line) and "Fit on Ligand" trend (pink line), are depicted in Figure 8B for compound 16 and in Figure S2 for indinavir. Compound 16 interacted with residues (Gly_143, Ser_144, Cys_145, and His_164) upon docking in the absence of water.

In the presence of water molecules, only one hydrogen bond interaction was persistent with Gly_143, observed during MD simulation (Table 4 , entry 2). This observation showed the importance of water molecules within binding pockets of protein 3CL pro for ligand 16. The detailed interaction of compound 16 with binding site residues of 3CL pro were studied and are presented in Figure 9 , where interacting residues include Thr_26, Leu_27, His_41, Ser_46, Met_49, Asn_119, Phe_140, Leu_141, Asn_142, Gly_143, Ser_144, Cys_145, His_163, His_164, Met_165, Glu_166, Pro_168, His_172, and Gln_189. The interacting residue with (Table S5 , Supporting Information). Compound 16 interacted with Leu_27, His_41, Met_49, and Met_165 residues of proteins forming hydrophobic interactions and with Asn_142, Gly_143, Ser_144, Cys_145, His_163, His_164, and Glu_166 forming H-bondwater interactions. There was no detectable ionic interaction for the 16-3CL pro complex as depicted in Figure 10 . The contacts formed by proteins with ligand 16 over the course of the trajectory are presented in the top panel and bottom panel in Figure 11 , showing that the residues interacted with the ligand in each trajectory frame. Some protein residues showed more than one specific contact with the ligand, which are described with a darker shade of orange color. Overall, six parameters 35 were analyzed to elucidate the stability of ligand 16 in the 3CL pro receptor during the simulation of 100 ns as described in Figure 12 . While the simulation process ligand RMSD remained constant, the overall RMSD of compound 16 was up to 2.771 Å. In the initial stage, fluctuation was observed from 0 to 18 ns, and afterward, a constant RMSD was observed during the entire simulation process. Fluctuation for the radius of gyration were noted until 40 ns, and subsequently, a stable conformation was obtained during the complete simulation process. The radius of gyration throughout the 100 ns simulation ranged from 3.275 to 4.524 Å for compound 16. The SASA plot revealed a fluctuating pattern for the initial 42 ns and then became stabilized until simulations were completed. MolSA and PSA plots also suggested stability of ligand 16 during the simulation process. Initially, compound 16 showed intramolecular H-bonds, which became stabilized after protein interaction, and no intramolecular H-bonds were observed at the end.

A 2D schematic representation for compound 16 is presented with color-coded rotatable bonds ( Figure 13 ). The rotatable torsional bond of compound 16 was supplemented by a dial (radial) plot and the same color bar plots. The radial plot explains the torsion angle conformation during simulation. The simulation starts from the center of the radial plot, and the time progress was plotted radially toward the outside. The probability density of the torsion angle was summarized by bar plots, which were recapitulating the data on the radial plots. The Y-axis of the bar plots revealed the potential of the rotatable bond, which are expressed in kcal/mol. The radial and bar diagram explained the torsion potential relationships and the conformational strain of compound 16 conserving a protein-bound conformation.

COVID-19 is continuing to become a global burden on human health, and economic losses remain unabated. A rapid progress, particularly in vaccine and therapeutic development, is essential to overcome the further explosion in spread and loss of human life from COVID-19. The structure of a protein target is considerably helpful in identifying and designing the potential drug candidates. Virtual screening remains one of the incredible approaches for structure-based design of chemical scaffolds against a known target protein binding well within the active site.

In summary, we have screened approved antiviral drugs against 3CL pro . Our in silico screening results indicated that indinavir, a known inhibitor of HIV protease, has high potential against the main protease, 3CLpro of SARS-CoV-2, and thus was selected as a positive control for the design of new drug candidates based on the HEA scaffold. Molecular docking of newly designed compounds was carried out, and a total of 25 analogs were identified with improved or similar Journal of Chemical Information and Modeling pubs.acs.org/jcim Article stabilities of the 16-3CL pro complex and a protein-bound conformation was confirmed by torsional analysis, suggesting suitability as a potent candidate for further in vitro and in vivo explorations as an explorative drug for use against SARS-CoV-2.

■ ASSOCIATED CONTENT * sı Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jcim.0c00326. Figures S1−S5 (simulation quality parameters for 100 ns simulation for indinavir-3CL pro complex, RMSF plot for indinavir-3CL pro complex, and residues involved in secondary structure for compound 16-3CL pro , Indinavir-3CL pro , and unligated-3CL pro complex.) Tables S1− S5 (list of molecules on the basis of docking score and XP Gscore (kcal/mol) against target protein; average value of total energy (E), potential energy (E_p), pressure (P), temperature (T), and volume (V) for 16− 3CL pro , and indinavir-3CL pro complexes; the average RMSD for backbone, Cα, and side chain of indinavir and unligated-3CL pro complex; percentage composition of secondary structure element). (PDF)

Coronavirus 229E-Related Pneumonia in Immunocompromised Patients

Coronavirus infection of the central nervous system: host−virus stand-off

Feline Coronavirus Type II Strains 79−1683 and 79−1146 Originate from a Double Recombination between Feline Coronavirus Type I and Canine Coronavirus

Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV

Discovery of a Novel Family of SARS-CoV Protease Inhibitors by Virtual Screening and 3D-QSAR Studies

Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics

Coronavirus Disease COVID-19: A New Threat to Public Health

Situation Report 110

COVID-2019): Situtation Reports 72− 101

The 2019 novel cornoavirus pneumonia with onset of oculomotor nerve palsy: a case study

The crystal structure of COVID-19 main protease in complex with an inhibitor N3. Protein Data Bank

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design

The newly emerged SARS-like coronavirus HCoV-EMC also has an ″Achilles' heel″: current effective inhibitor targeting a 3C-like protease

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

Inhibitors of SARS-3CLpro: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation Studies

Virtual Screening of Novel Noncovalent Inhibitors for SARS-CoV 3C-like Proteinase

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

Protein Preparation Wizard, Schrodinger Release

Schrodinger Release 2020-1: Schrodinger, LLC: New York

Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling

Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin V to aid in the design of potent inhibitors

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

New York, 2020. (b) Maestro-Desmond Interoperability Tools

First Case of 2019 Novel Coronavirus in the United States

A trial of lopinavir−ritonavir in adults hospitalized with severe Covid-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking. Preprints

Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication

Fluorinated scaffolds for antimalarial drug discovery

Chemical libraries targeting Liver Stage Malarial infection

Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins

Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors

Hydroxyethylamine derivatives as HIV-1 protease inhibitors: a predictive QSAR modelling study based on Monte Carlo optimization

Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation

Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity

Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state-docking and computer simulations of a homology model

FlexE: efficient molecular docking considering protein structure variations1 1Edited by